台灣臨床試驗主持人資料庫|TPIDB

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberEidos AG10-333

NCT Number(ClinicalTrials.gov Identfier)NCT04418024

2020-11-01 - 2022-06-30

Phase III

Recruiting2

ICD-10E85.0

Non-neuropathic heredofamilial amyloidosis

ICD-10E85.1

Neuropathic heredofamilial amyloidosis

ICD-10E85.2

Heredofamilial amyloidosis, unspecified

ICD-10E85.3

Secondary systemic amyloidosis

ICD-10E85.4

Organ-limited amyloidosis

ICD-10E85.8

Other amyloidosis

ICD-10E85.9

Amyloidosis, unspecified

ICD-9277.3

Amyloidosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)

Trial Applicant
Sponsor

Eidos Therapeutics Inc.
Trial scale

Multi-Regional Multi-Center
Update

2025/08/20

Investigators and Locations

Principal Investigator Long-Sun Ro Division of Neurology

Linkou Chang Gung Medical Foundation

Co-Principal Investigator

謝珮甄 Division of Neurology
呂國榮 Division of Neurology
Hong-Chou Kuo Division of Neurology
張國軒 Division of Neurology

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chi-Chao Chao Division of Neurology

National Taiwan University Hospital

Co-Principal Investigator

Ming-Jen Lee Division of Neurology
Jen Jen and I Su Division of Neurology
HSUEH-WEN HSUEH Division of Neurology
LI-KAI TSAI Division of Neurology
高伊慧 Division of Neurology
YEN-HUNG LIN Division of General Internal Medicine
SUNG-TSANG HSIEH Division of Neurology
SHIN-JOE YEH Division of Neurology
CHIH-HAO CHEN Division of Neurology

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Symptomatic Transthyretin Amyloid Polyneuropathy

Objectives

Withdrawn (After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.)

Test Drug

AG10

Active Ingredient

AG10 HCl

Dosage Form

tablet

Dosage

400

Endpoints

Withdrawn
(After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.)

Inclution Criteria

Withdrawn
(After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.)

Exclusion Criteria

Withdrawn
(After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.)

The Estimated Number of Participants

Taiwan

28 participants
Global

161 participants